Intrathecal prophylaxis following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Varadi
G
G
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Lossos
A
A
Nagler
A
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D016400:Lymphoma, Large-Cell, Immunoblastic / Q000532:radiotherapy / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011859:Radiography; D019172:Transplantation Conditioning / Q000379:methods*; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate